We randomly allocated patients ( 2:1 ; with a computer-generated unicentric randomisation list [ prepared by the study funder ] and interactive voice response system ; block size of six ; stratified by metastatic site [ single vs multiple organs ] and time from diagnosis of metastatic disease [ < 18 months vs 18 months ] ) to receive oral regorafenib 160 mg once daily or placebo on days 1-21 of each 28 day cycle ; patients in both groups were also to receive best supportive care .